Vision-related function after ranibizumab treatment for diabetic macular edema: Results from RIDE and RISE

Ophthalmology

Volumn 121, Issue 12, 2014, Pages 2461-2472

  Bressler, Neil M ^a   Varma, Rohit ^b   Suñer, Ivan J ^c   Dolan, Chantal M ^d   Ward, James ^d   Ehrlich, Jason S ^d   Colman, Shoshana ^d   Turpcu, Adam ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Retina Associates of Florida   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

25 ITEM NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE SCORE; AGE RELATED MACULAR DEGENERATION; ARTICLE; ASSESSMENT OF HUMANS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISION; VISUAL ACUITY; VISUAL IMPAIRMENT; ADULT; AGED; CLINICAL TRIAL; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; FEMALE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; QUESTIONNAIRE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; QUESTIONNAIRES; VISUAL ACUITY; YOUNG ADULT;

EID: 84922239880     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.07.008     Document Type: Article

References (18)

1. M.J. Elman, L.P. Aiello, and R.W. Beck Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 2010 1064 1077.e35
2. P. Mitchell, F. Bandello, and U. Schmidt-Erfurth The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema Ophthalmology 118 2011 615 625
3. Ohji M, Ishibashi T. Efficacy and safety of ranibizumab 0.5 mg as monotherapy or adjunctive to laser versus laser monotherapy in Asian patients with visual impairment due to diabetic macular edema: 12-month results of the REVEAL study. [ARVO abstract 4664]. Available at http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=33d868e0-ab8d-406c-b25e-15fff568bf34&cKey=4a8712da-de4e-4f18-a3ad-6140801095c7&mKey=f0fce029-9bf8-4e7c-b48e-9ff7711d4a0e. Accessed on December 18, 2013.
4. Q.D. Nguyen, D.M. Brown, and D.M. Marcus Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 119 2012 789 801
5. Mangione CM. The National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25). Version 2000. Available at: http://www.nei.nih.gov/resources/visionfunction/vfq-ia.pdf Accessed May 7, 2012.
6. P. Mitchell, N. Bressler, and K. Tolley Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial JAMA Ophthalmol 131 2013 1339 1347
7. N.M. Bressler, T.S. Chang, and I.J. Suner Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR Ophthalmology 117 2010 747 756.e4
8. T.E. Clemons, E.Y. Chew, S.B. Bressler, and W. McBee National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS report no. 10 Arch Ophthalmol 121 2003 211 217
9. R.W. Beck, P.S. Moke, and A.H. Turpin A computerized method of visual acuity testing: adaptation of the Early Treatment of Diabetic Retinopathy Study testing protocol Am J Ophthalmol 135 2003 194 205
10. D.W. Blackhurst, M.G. Maguire for the Macular Photocoagulation Study Group Reproducibility of refraction and visual acuity measurement under a standard protocol Retina 9 1989 163 169
11. C.M. Mangione, P.P. Lee, and P.R. Gutierrez Development of the 25-item National Eye Institute Visual Function Questionnaire Arch Ophthalmol 119 2001 1050 1058
12. C.M. Mangione, P.P. Lee, J. Pitts the NEI-VFQ Field Test Investigators Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ) Arch Ophthalmol 116 1998 1496 1504
13. A.S. Lindblad, and T.E. Clemons Responsiveness of the National Eye Institute Visual Function Questionnaire to progression to advanced age-related macular degeneration, vision loss, and lens opacity: AREDS report no. 14 Arch Ophthalmol 123 2005 1207 1214
14. P.H. Miskala, B.S. Hawkins, and C.M. Mangione Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization - SST report no. 1 Arch Ophthalmol 121 2003 531 539
15. I.J. Suner, G.T. Kokame, and E. Yu Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials Invest Ophthalmol Vis Sci 50 2009 3629 3635
16. N.M. Bressler, T.S. Chang, and J.T. Fine Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial Arch Ophthalmol 127 2009 13 21
17. T.S. Chang, N.M. Bressler, and J.T. Fine Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial Arch Ophthalmol 125 2007 1460 1469
18. R. Varma, N.M. Bressler, and I. Suner Improved vision-related function after ranibizumab in patients with macular edema secondary to retinal vein occlusion: results of BRAVO and CRUISE clinical trials Ophthalmology 119 2012 2108 2118